Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,157
datasets available to search
ShareScore release 0.9.0
Dataset results
4,157 results for “Survival.”
Tumor cells that survive oncogenic pathway inhibition exhibit cellular dormancy
GEO Series GSE60611. Mus musculus. 23 samples. Type: Expression profiling by array.
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
GEO Series GSE105447. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing.
The levels of human PDAC microRNAs’ expression in 10 patients with longest survival and 10 with shortest survival were selected
GEO Series GSE106198. Homo sapiens. 20 samples. Type: Non-coding RNA profiling by array.
A β-catenin-regulated RNA processing transcriptional program imposes chemotherapy resistance and predicts T-ALL patient survival associated with high BRCA1 levels [ChIP-Seq]
GEO Series GSE180650. Homo sapiens. 29 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
CHD4 acts as a critical regulator in the survival of spermatogonial stem cells in mice
GEO Series GSE193071. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
The microRNA-200 family regulates pancreatic beta-cell survival in type 2 diabetes (islet)
GEO Series GSE58488. Mus musculus. 2 samples. Type: Expression profiling by array.
Enhancer priming role of FOXO1 sustains pro-survival BCR signaling in lymphoma
GEO Series GSE303985. Homo sapiens. 24 samples. Type: Non-coding RNA profiling by high throughput sequencing.
The General Transcription Factor TAF7 is Essential for Embryonic Development but Not Essential for the Survival or Differentiation of Mature T Cells (T cell data)
GEO Series GSE34795. Mus musculus. 2 samples. Type: Expression profiling by array.
The microRNA-200 family regulates pancreatic beta-cell survival in type 2 diabetes (Min6 cells)
GEO Series GSE58487. Mus musculus. 2 samples. Type: Expression profiling by array.
EZH2 reads DNA 6mA to regulate survival and drug resistance of human head and neck squamous carcinoma by suppressing RIOX2-CDKN1A-NRF2 signaling axis [MeDIP-ChIP-seq-shRNA]
GEO Series GSE212437. Homo sapiens. 17 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Methylation profiling by high throughput sequencing.
Chronic acidosis drives reversible metabolic plasticity and survival adaptation in multiple myeloma
GEO Series GSE314522. Homo sapiens. 6 samples. Type: Expression profiling by array.
Early Relapse in ALL is identified by Time To Leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways
Gene expression analysis identified a specific signature of differentially expressed genes discriminating TTLshort and TTLlong phenotypes. Gene expression signatures of xenografted leukemia samples with different TTL phenotypes were analyzed on cohorts of pediatric BCP-ALL patients.
Bone morphogenetic protein-7 is a MYC target with pro-survival functions in childhood medulloblastoma
Medulloblastoma (MB) is the most common malignant brain tumor in children, among whom overexpression or amplification of MYC oncogenes has been associated with poor clinical outcome. Although the MYC functions during normal development and oncogenesis in various systems have been extensively investigated, the transcriptional targets mediating MYC effects in MB are still elusive. Their identification and roles during MB onset and progression are important and will ultimately suggest novel potential therapeutic targets. cDNA microarray analysis was used to compare the effects of overexpressing and silencing MYC on the transcriptome of a MB-derived cell line. We identified 209 genes with potential relevance to MYC-dependent cellular responses in MB. Among the MYC-responsive genes, we found members of the bone morphogenetic protein (BMP) signaling pathway, which plays a crucial role during the development of the cerebellum. In particular, the cytokine gene BMP7 was identified as a direct target of MYC in MB cells. Similar to the effect induced by BMP7 silencing by siRNA, the use of a small-molecule inhibitor of the BMP/SMAD signaling pathway reduced cell viability in a panel of MB cells. Altogether, our findings indicate that high MYC levels drive BMP7 expression in MB to induce pro-survival and pro-proliferative cellular pathways. This observation suggests that targeting the BMP/SMAD pathway may be a new therapeutic concept for the treatment of childhood MB.
Incidence and survival of central nervous system tumors in childhood and adolescence in Girona (Spain) 1990-2013
Pediatric central nervous system (CNS) tumors are the second most frequent neoplasm in children under 14 years and the third in the range of 15-19-year-old adolescents, but epidemiological data on these tumors have been sparsely reported in the medical literature. We have performed a retrospective population-based study to determine the incidence and survival of these primary CNS tumors in pediatrics and during adolescence in the population of Girona and compare them with series from Spain, Europe and worldwide.
Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016
This study investigated the incidence and relative survival rates for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in Korea.
Dataset related to article "Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma"
<p>PURPOSE:</p> <p>To appraise the ability of a radiomics signature to predict clinical outcome after stereotactic body radiation therapy (SBRT) for pancreas carcinoma.</p> <p>METHODS:</p> <p>A cohort of 100 patients was included in this retrospective, single institution analysis. Radiomics texture features were extracted from computed tomography (CT) images obtained for the clinical target volume. The cohort of patients was randomly divided into two separate groups for the training (60 patients) and validation (40 patients). Cox regression models were built to predict overall survival and local control. The significant predictors at univariate analysis were included in a multivariate model. The quality of the models was appraised by means of area under the curve and concordance index.</p> <p>RESULTS:</p> <p>A clinical-radiomic signature associated with Overall Survival (OS) was found significant in both training and validation sets (p = 0.01 and 0.05 and concordance index 0.73 and 0.75 respectively). Similarly, a signature was found for Local Control (LC) with p = 0.007 and 0.004 and concordance index 0.69 and 0.75. In the low risk group, the median OS and LC in the validation group were 14.4 and 28.6 months while in the high-risk group were 9.0 and 17.5 months respectively.</p> <p>CONCLUSION:</p> <p>A CT based radiomic signature was identified which correlate with OS and LC after SBRT and allowed to identify low and high-risk groups of patients.</p>
Dataset related to article "Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy."
<p>PURPOSE:</p> <p>This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors.</p> <p>METHODS AND MATERIALS:</p> <p>Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent.</p> <p>RESULTS:</p> <p>The study included 358 patients. With a median follow-up of 31.83 months, local control at 6 and 24 months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24 months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7 months (95% confidence interval, 29.66-43.83). OS at 6 and 24 months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P = .001) and nodal metastases (HR, 0.44 [0.24-0.78]; P = .005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P = .013), increasing age (HR, 1.02 [1.01-1.04]; P = .002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P = .001) were all independent predictors of shorter OS. Local response was associated with OS.</p> <p>CONCLUSIONS:</p> <p>SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients'' prognosis, also underlying its relevance in a metastatic setting.</p>
Dataset related to article "Survival outcomes of robotic radical hysterectomy for early stage cervical cancer: A 9-year study."
<p>BACKGROUND:</p> <p>Recently, the results of a RCT have raised concerns on the management of cervical cancer through a minimally invasive approach. This study reports on the outcomes of patients with early stage cervical cancer submitted to robotics.</p> <p>METHODS:</p> <p>Retrospective review of a consecutive series of patients with an early cervical cancer treated with robotics at a single Institution over a 9-year period.</p> <p>RESULTS:</p> <p>A total of 91 women were managed; 39 (41.1%) had cervical adenocarcinoma. One (1.1%) conversion to laparotomy and one (1.1%) intraoperative complication occurred. Five (5.5%) patients experienced postoperative (>G2) complications; 24 (26.4%) patients required further adjuvant therapies. After a median follow-up of 40.7 (3.8-96.6) months, the DFS and OS were 90.4 (95%CI 85.3-95.6)% and 94.5 (95%CI 91.8-97.2)%, respectively.</p> <p>CONCLUSIONS:</p> <p>According to the available literature, the survival outcomes of this series of RRH for ECC are not inferior to what recorded in the past by an open approach.</p>
Cancer-specific Survival of Uveal Melanoma Patients by Diagnosis Era (A, C, D, E) and Tumor Stage (B, F,G,H)
<p>Cancer-specific Survival of Uveal Melanoma Patients by Diagnosis Era (A, C, D, E) and Tumor Stage (B, F,G,H)</p>
Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.
<p>Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Objective: </strong> The objective of this study was to analyze preoperative risk factors affecting long-term survival and the occurrence of stroke in patients older than 80 years undergoing either carotid endarterectomy (CEA) or carotid artery stenting (CAS) for carotid stenosis.</p> <p><strong>Methods: </strong> Data of all consecutive patients treated from January 1999 to December 2017 were retrospectively reviewed and outcomes analyzed. Kaplan-Meier analysis was used to estimate long-term survival and the risk of stroke for both groups. Cox proportional hazards analysis was used to assess the relative risk of all-cause mortality and long-term stroke for patients in the presence of selected comorbidities, including preoperative symptoms, coronary artery disease, chronic renal failure, atrial fibrillation (AF), hypertension, diabetes mellitus, and dyslipidemia. A P value <.05 was considered statistically significant.</p> <p><strong>Results: </strong> A total of 473 patients older than 80 years (298 men [63%]) underwent either CEA (n = 178) or CAS. At 30 days, one patient died in the CEA group of unrelated causes; no deaths were recorded after CAS (0.6% vs 0%; P = .18). At 5 years, survival was 67.6% ± 4.9% after CEA and 90.2% ± 2.3% after CAS (P < .0001). The main cause of death after CEA and CAS was a neoplasm. Estimated freedom from any stroke at 5 years was 97.3% ± 0.5% after CEA and 93.2% ± 1.2% after CAS (P = .07). The presence of preoperative AF significantly affected long-term mortality after CAS (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.34-1.98; P = .04) as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF was the only factor that significantly affected the occurrence of long-term stroke after both CAS (HR, 2.28; 95% CI, 1.86-5.63; P = .001) and CEA (HR, 3.45; 95% CI, 2.29-8.19; P = .005).</p> <p><strong>Conclusions: </strong> Both CEA and CAS showed low 30-day mortality and any-stroke rates in patients older than 80 years. In the long term, survival was significantly better after CAS; however, deaths after CEA and CAS were mainly unrelated to the procedure. No significant differences were recorded in the occurrence of any stroke in the long term. The presence of preoperative AF significantly affected long-term survival after CAS as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF also significantly affected long-term risk of stroke after both CAS and CEA.</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.